These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 34440660)
1. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer. Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW Cells; 2021 Jul; 10(8):. PubMed ID: 34440660 [TBL] [Abstract][Full Text] [Related]
2. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. Lin Y; Zhang J; Li Y; Guo W; Chen L; Chen M; Chen X; Zhang W; Jin X; Jiang M; Xiao H; Wang C; Song C; Fu F J Transl Med; 2022 Jan; 20(1):17. PubMed ID: 34991621 [TBL] [Abstract][Full Text] [Related]
3. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc. Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349 [TBL] [Abstract][Full Text] [Related]
4. Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer. Umar SM; Kashyap A; Kahol S; Mathur SR; Gogia A; Deo SVS; Prasad CP Exp Cell Res; 2020 Nov; 396(1):112282. PubMed ID: 32919954 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of GLUT3 promotes metastasis of triple-negative breast cancer by modulating the inflammatory tumor microenvironment. Tsai TH; Yang CC; Kou TC; Yang CE; Dai JZ; Chen CL; Lin CW J Cell Physiol; 2021 Jun; 236(6):4669-4680. PubMed ID: 33421130 [TBL] [Abstract][Full Text] [Related]
6. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer. Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269 [TBL] [Abstract][Full Text] [Related]
7. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro. Lim JP; Shyamasundar S; Gunaratne J; Scully OJ; Matsumoto K; Bay BH BMC Cancer; 2017 Mar; 17(1):201. PubMed ID: 28302118 [TBL] [Abstract][Full Text] [Related]
8. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer. Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449 [TBL] [Abstract][Full Text] [Related]
9. MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation. Gu P; Ding W; Zhu W; Shen L; Zhang L; Wang W; Wang R; Wang W; Wang Y; Yan B; Sun X Int Immunopharmacol; 2024 Dec; 142(Pt B):113191. PubMed ID: 39317050 [TBL] [Abstract][Full Text] [Related]
10. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients. Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197 [TBL] [Abstract][Full Text] [Related]
11. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells. Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450 [TBL] [Abstract][Full Text] [Related]
13. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. Lim JP; Nair S; Shyamasundar S; Chua PJ; Muniasamy U; Matsumoto K; Gunaratne J; Bay BH Cancer Lett; 2019 Jun; 452():119-131. PubMed ID: 30905819 [TBL] [Abstract][Full Text] [Related]
14. Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer. Zhong PC; Shu R; Wu HW; Liu ZW; Shen XL; Hu YJ Exp Biol Med (Maywood); 2021 Mar; 246(5):560-571. PubMed ID: 33243007 [TBL] [Abstract][Full Text] [Related]
15. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Huang YH; Chu PY; Chen JL; Huang CT; Huang CC; Tsai YF; Wang YL; Lien PJ; Tseng LM; Liu CY Sci Rep; 2021 Jun; 11(1):12171. PubMed ID: 34108545 [TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway. Wang L; Kang FB; Wang J; Yang C; He DW Anticancer Drugs; 2019 Mar; 30(3):225-232. PubMed ID: 30334817 [TBL] [Abstract][Full Text] [Related]
17. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma. Zhou LL; Ni J; Feng WT; Yao R; Yue S; Zhu YN; Tang HY; Lv LY; Feng JF; Zhu WG Exp Cell Res; 2017 Dec; 361(1):126-134. PubMed ID: 29024700 [TBL] [Abstract][Full Text] [Related]
18. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002 [TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. Zheng S; Yang L; Zou Y; Liang JY; Liu P; Gao G; Yang A; Tang H; Xie X J Hematol Oncol; 2020 Mar; 13(1):17. PubMed ID: 32138762 [TBL] [Abstract][Full Text] [Related]
20. Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple-Negative Breast Cancer. Tian W; Zhu L; Luo Y; Tang Y; Tan Q; Zou Y; Chen K; Deng X; Tang H; Li H; Cai M; Xie X; Ye F Adv Sci (Weinh); 2024 Sep; 11(36):e2309903. PubMed ID: 39073262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]